Health Care • Biotechnology: Pharmaceutical Preparations
$7.77 ▼ -0.24
(-3.00%)
MKT CAP: $51.1M • VOL: 2.7K
52W L $6 52W H $12
XLO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $43.8M | $6.3M | $0 |
| YoY Revenue Growth % | +589.9% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.0M | -$60.6M | -$79.1M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$35.0M | -$58.2M | -$76.4M |
| EBITDA (Normalized) | -$41.6M | -$60.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.0M | -$18.4M | -$68.6M |
| Capital Expenditures (CapEx) | $518.0K | $36.0K | — |
| Free Cash Flow (FCF) | -$5.5M | -$18.4M | -$68.6M |
| FCF Margin % | -12.6% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $137.5M | $55.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $35.3M | $17.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR XLO.